ScholarLens Back to search
2017•Zhonghua chuanranbing zazhiRequires access

Protein induced by vitamin K absence or antagonist II application research in hepatocellular carcinoma

Junli Li, Jia Shang, Wěi Li, Huibin Ning, Jia He

Open publisher page 0 citations

Abstract

Objective To investigate the diagnostic value and biological features of protein induced by vitamin K absence or antagonist Ⅱ (PIVKA-Ⅱ) and alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC). Methods Serum samples of 72 patients with HCC (HCC group), 54 patients with hepatitis B cirrhosis (cirrhosis group) and 30 patients with chronic hepatitis B (CHB) without cirrhosis (CHB group) were tested with the PIVKA-Ⅱ and AFP detection kits. Diagnostic efficacies of PIVKA-Ⅱ and AFP were evaluated by receiver-operating characteristic curve (ROC). The cut-off value of PIVKA-Ⅱ for diagnose HCC was also determined. Sensitivities and specificities of PIVKA-Ⅱ and AFP were compared. Results The medians of PIVKA-Ⅱ levels in HCC group, cirrhosis group and CHB group were 14.36, 11.21, and 329.88 mAU/mL, respectively. The serum PIVKA-Ⅱ level in the HCC group was significantly higher than that in cirrhosis group (U=342.50, P 0.05). The serum PIVKA-Ⅱ levels in patients with BCLC stage A, B, C in HCC group were 22.13, 345.46, and 13 057.72 mAU/mL, respectively. After comparison of stage A and C with stage B, the differences were both statistically significant (stage A to B: U=119.0, P<0.01; stage B to C: U=158.0, P<0.01). The sensitivity and specificity of PIVKA-Ⅱ with a cut-off value of 30.01 mAU/mL by means of Youden index were 0.750 and 1.000, respectively. When combined PIVKA-Ⅱ with AFP, the sensitivity and specificity were 0.800 and 0.964, respectively. The area under the curve (AUC) was highest (AUC=0.930, 95%CI: 0.852—0.974), and significantly higher than that using PIVKA-Ⅱ alone (AUC=0.892, 95%CI: 0.834—0.950, χ2=21.43, P<0.01). Conclusions The diagnostic value of serum PIVKA-Ⅱ is superior to AFP. Combined with AFP, serum PIVKA-Ⅱ can improve the detection rate of HCC, and has advantages during the development of HCC and can be used to monitor the condition of HCC patients. Key words: PIVKA-Ⅱ; Carcinoma, hepatocellular; Diagnosis

About this research paper

What this paper is about

Objective To investigate the diagnostic value and biological features of protein induced by vitamin K absence or antagonist Ⅱ (PIVKA-Ⅱ) and alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC). Methods Serum samples of 72 patients with HCC (HCC group), 54 patients with hepatitis B cirrhosis (cirrhosis group) and 30 patients with chronic hepatitis B (CHB) without cirrhosis (CHB group) were tested with the PIVKA-Ⅱ and AFP detection kits. Diagnostic efficacies of PIVKA-Ⅱ and AFP were evaluated by receiver-operating characteristic curve (ROC). The cut-off value of PIVKA-Ⅱ for diagnose HCC was also determined. Sensitivities and specificities of PIVKA-Ⅱ and AFP were compared. Results The medians of PIVKA-Ⅱ levels in HCC group, cirrhosis group and CHB group were 14.36, 11.21, and 329.88 mAU/mL, respectively. The serum PIVKA-Ⅱ level in the HCC group was significantly higher than that in cirrhosis group (U=342.50, P 0.05). The serum PIVKA-Ⅱ levels in patients with BCLC stage A, B, C in HCC group were 22.13, 345.46, and 13 057.72 mAU/mL, respectively. After comparison of stage A and C with stage B, the differences were both statistically significant (stage A to B: U=119.0, P<0.01; stage B to C: U=158.0, P<0.01). The sensitivity and specificity of PIVKA-Ⅱ with a cut-off value of 30.01 mAU/mL by means of Youden index were 0.750 and 1.000, respectively. When combined PIVKA-Ⅱ with AFP, the sensitivity and specificity were 0.800 and 0.964, respectively. The area under the curve (AUC) was highest (AUC=0.930, 95%CI: 0.852—0.974), and significantly higher than that using PIVKA-Ⅱ alone (AUC=0.892, 95%CI: 0.834—0.950, χ2=21.43, P<0.01). Conclusions The diagnostic value of serum PIVKA-Ⅱ is superior to AFP. Combined with AFP, serum PIVKA-Ⅱ can improve the detection rate of HCC, and has advantages during the development of HCC and can be used to monitor the condition of HCC patients. Key words: PIVKA-Ⅱ; Carcinoma, hepatocellular; Diagnosis

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the diagnostic value and biological features of protein induced by vitamin K absence or antagonist Ⅱ (PIVKA-Ⅱ) and alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC). Methods Serum samples of 72 patients with HCC (HCC group), 54 patients with hepatitis B cirrhosis (cirrhosis group) and 30 patients with chronic hepatitis B (CHB) without cirrhosis (CHB group) were tested with the PIVKA-Ⅱ and AFP detection kits. Diagnostic efficacies of PIVKA-Ⅱ and AFP were evaluated by receiver-operating characteristic curve (ROC). The cut-off value of PIVKA-Ⅱ for diagnose HCC was also determined. Sensitivities and specificities of PIVKA-Ⅱ and AFP were compared. Results The medians of PIVKA-Ⅱ levels in HCC group, cirrhosis group and CHB group were 14.36, 11.21, and 329.88 mAU/mL, respectively. The serum PIVKA-Ⅱ level in the HCC group was significantly higher than that in cirrhosis group (U=342.50, P 0.05). The serum PIVKA-Ⅱ levels in patients with BCLC stage A, B, C in HCC group were 22.13, 345.46, and 13 057.72 mAU/mL, respectively. After comparison of stage A and C with stage B, the differences were both statistically significant (stage A to B: U=119.0, P<0.01; stage B to C: U=158.0, P<0.01). The sensitivity and specificity of PIVKA-Ⅱ with a cut-off value of 30.01 mAU/mL by means of Youden index were 0.750 and 1.000, respectively. When combined PIVKA-Ⅱ with AFP, the sensitivity and specificity were 0.800 and 0.964, respectively. The area under the curve (AUC) was highest (AUC=0.930, 95%CI: 0.852—0.974), and significantly higher than that using PIVKA-Ⅱ alone (AUC=0.892, 95%CI: 0.834—0.950, χ2=21.43, P<0.01). Conclusions The diagnostic value of serum PIVKA-Ⅱ is superior to AFP. Combined with AFP, serum PIVKA-Ⅱ can improve the detection rate of HCC, and has advantages during the development of HCC and can be used to monitor the condition of HCC patients. Key words: PIVKA-Ⅱ; Carcinoma, hepatocellular; Diagnosis

Key concepts: Hepatocellular carcinoma, Cirrhosis, Gastroenterology, Internal medicine, Medicine, Stage (stratigraphy), Chronic hepatitis, Hepatitis B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Protein induced by vitamin K absence or antagonist II application research in hepatocellular carcinoma — Research Paper | ScholarLens